Follow the link to the latest Patent Docs post on Myriad and its defense of its patent suite for BRCA1 & 2 cancer testing versus the likes of Ambry Genetics and other providers who look to be trying to horn in on Myriads monopoly position for this type of genetic analysis.
Myriad, buoyed by the recent Supreme Court position, is now asserting its patent rights to cDNA sequences for the BRCA genes that are the core of its test. Plus, it makes clear that its testing service, based on an extensive database of patient data with BRCA variants, will deliver better results to patients as it can give a definitive diagnosis/prognosis for varians over 97% of the time compared to a competitors' 70-75%. Thus you get what you pay for if you would opt to buy services from an Ambry at say $2280 per test vs the Myriad going rate of $4040. Myriad filed its suit though, as it is obviousl they fear 3rd party payers may in fact make such a choice for a cheaper test -- without bothering to understand the value of a greater certainty in a Myriad result.
Bottom line: the post seems to substantiate that Myriad is in good position to put up a stalwart defense, and will likely prevail in protecting its patent suite (and purported $500 M investment to date) and ultimately its business position and revenues. Like it or lump it.
Posted by Bruce Lehr Aug 1st 2013.